Subscribe to Email Alerts
INOVIQ
  • About Us
    • About INOVIQ
    • Market Opportunity
    • Board
    • The Team
    • Partners
    • Distributors
    • Compliance
    • Careers
  • Technology
    • Our Science
    • NETs Platform
    • SubB2M Platform
    • BARD1 Biomarker Technology
    • hTERT ICC Assay
    • Intellectual Property
    • Publications
    • Business Development
  • Products
    • Our Products
    • EXO-NET® Pan-Exosome
      • Product Overview
      • Data & Figures
      • Ordering
      • Resources
        • Publications
    • hTERT ICC Test
  • Pipeline
    • Development Pipeline
    • SubB2M CA15-3
    • SubB2M CA125
  • Investors
    • Investor Overview
    • ASX Announcements
    • Annual & Financial Reports
    • Presentations
    • Share Price Information
    • AGM
    • INOVIQ Fact Sheet
    • Corporate Governance
    • Shareholder Services
    • FAQ
    • Analyst Reports
    • Conferences & Events
  • Media
    • INOVIQ in the News
  • Contact
    • Contact Us
    • Subscribe to Email Alerts

SubB2M CA125

Heading &

Sub-heading can be edited through HQI

Pipeline > SubB2M CA125
  • Development Pipeline
  • SubB2M CA15-3
  • SubB2M CA125

SubB2M CA125

EXO-Ovarian Cancer Test | Improved OC

 

Progressing towards clinical validation.

1Cancer Today (iarc.fr) ; 2Ovarian Cancer Diagnostics Market Size Worth US$ 1.8 Bn by (globenewswire.com)

Quick Links

Contact Us

Melbourne:
T: +61 3 9548 7586
23 Normanby Road
Notting Hill VIC 3168
Australia

US Office:
987 Old Eagle School Road, Suite 709
Wayne, PA 19087

Online:
E: [email protected]
W: www.inoviq.com

Email Alerts

Subscribe to Email Alerts

Follow Us

Copyright © INOVIQ
Site Map Privacy Search
Site by